INBX - Company ID 0001739614
Inhibrx, Inc. trades as INBX and has a market capitalization of $1.53 B, making it the #2346 largest US-listed company by market value. This page tracks Inhibrx, Inc. through 261 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-05-29
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Over the last 4 fiscal years Inhibrx, Inc.'s revenue declined from $13.21M to $1.80M, a compound annual decline rate of 39.2%. Net profit margin compressed from -389.1% to -13408.9% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Passive ownership stake (update) | SC 13G/A | 2024-11-14 |
| 15-12G | - | 2024-06-10 |
| Passive ownership stake (update) | SC 13G/A | 2024-06-03 |
| Insider trade | 4 | 2024-06-03 |
| Insider trade | 4 | 2024-05-31 |
| Delisting notice | 25-NSE | 2024-05-30 |
| S-8 POS | - | 2024-05-30 |
| S-8 POS | - | 2024-05-30 |
Recent Corporate Highlights and Upcoming Milestones
The largest companies sharing Inhibrx, Inc.'s SEC industry classification (biological products, (no diagnostic substances)).
Inhibrx, Inc. (INBX) has a market capitalization of $1.53 B as of 2026-05-29, ranking #2346 among US-listed companies.